Miguel A. Climent - Publications

Perioperative therapy in muscle-invasive bladder cancer: real-world evidence from the MINOTAURO study.

Journal: ESMO real world data and digital oncology

Published: July 28, 2026

Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: April 16, 2026

Non-Cancer Causes of Death in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Analysis.

Journal: The Prostate

Published: January 12, 2026

Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: September 25, 2025

Association of PD-1, LAG-3 and TIM-3 expression on intratumoral CD8 T-cells with response to atezolizumab in a Real-World-Evidence biomarker study for advanced urothelial carcinoma patients.

Journal: Oncoimmunology

Published: August 08, 2025

SEOM-SOGUG clinical guideline for urothelial cancer (2025).

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: July 29, 2025

External validation of the heidenreich criteria for patients with post-chemotherapy residual masses of non-seminomatous germ cell tumor.

Journal: The Canadian journal of urology

Published: July 09, 2025

Corrigendum to "Prognostic Expression Signature of RB1, PTEN, and TP53 Genes in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors" [Eur. Urol. Open Sci. 70 (2024) 86-90].

Journal: European urology open science

Published: June 18, 2025

Clinical and Transcriptomic Characterization of Metastatic Hormone-Sensitive Prostate Cancer Patients with Low PTEN Expression.

Journal: International journal of molecular sciences

Published: May 30, 2025

Corrigendum to "Development and independent validation of a prognostic gene expression signature based on RB1, PTEN, and TP53 in metastatic hormone-sensitive prostate cancer patients" [Eur. Urol. Oncol. 7 (2024) 954-964].

Journal: European urology oncology

Published: May 27, 2025

Spatial architecture contributes to failure of bulk biomarker-guided neoadjuvant immunotherapy selection in bladder cancer: The DUTRENEO study.

Journal: Cell reports. Medicine

Published: February 22, 2025

First-line Pembrolizumab Plus Lenvatinib for Advanced Non-clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial.

Journal: European urology

Published: February 18, 2025